StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
223250.KQ$4505.00-2.49%
Fair $4505.00+0.0%

223250.KQ

DreamCIS, Inc.

Healthcare / Medical Care FacilitiesKOSDAQ

$4505.00

-115.00 (-2.49%)

Fairly Valued+0.0%Fair Value $4505.00Fund rank 34/100 · Data gapFallback financials|
SA 64/B
F-Score: 4/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 26% · confianza 25%

FCF escenarios

weak_data · normalized FCF $5.6B · quality 66.0/100

Data gap 34/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 53/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

64/100

B

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 223250.KQLocal privado en este navegador · DreamCIS, Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$107.2B

P/E

15.1x

↓

EV/EBITDA

7.3x

↓

ROE

9.3%

↑

Gross Margin

29.1%

↓

Debt/Equity

0.22

↓
52-Week Range$4505
$2910$8640

TradingView lightweight chart

223250.KQ price, volumen y niveles de valoración

Último $4,505Periodo -40.9%
Fair value: $4,505

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+19.7%

FCF CAGR

+16.6%

FCF margin

20.1%

FCF / Net income

1.88x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $66.63B · net income $7.13B · FCF $13.40B

2022-FY → 2025-FY

Gross margin

29.1%-6.6% pts

Operating margin

7.9%-7.1% pts

Net margin

10.7%-0.6% pts

FCF margin

20.1%-1.6% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$66.63B$66.63B$58.65B$47.84B$38.87B
Net Income$7.13B$7.13B$5.28B$3.74B$4.41B
EBITDA$14.03B$14.03B$8.85B$6.75B$7.12B
EPS298.00298.00221.00157.0048.50
Gross Margin29.1%29.1%30.5%27.0%35.7%
Operating Margin7.9%7.9%8.6%3.3%15.0%
Net Margin10.7%10.7%9.0%7.8%11.3%
Balance Sheet
Debt/Equity0.220.220.060.080.11
Current Ratio3.653.65———
Cash Flow
Free Cash Flow$13.40B$13.40B$-1.58B$5.65B$8.46B
Returns
ROE9.3%9.3%7.8%6.8%9.0%
Valuation
P/E15.1215.1213.6220.2960.31
EV/EBITDA7.287.285.9910.848.85
P/B1.411.411.061.361.36
Growth & Yield
Revenue Growth13.6%13.6%22.6%23.1%—
EPS Growth34.8%34.8%40.8%223.7%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

10.3%

razonable

EPS terminal req.

$399.74

Spread vs growth

24.6%

5Y implied EPS CAGR

10.2%

razonable

EPS terminal req.

$483.69

Spread vs growth

24.7%

10Y implied EPS CAGR

10.1%

razonable

EPS terminal req.

$778.99

Spread vs growth

24.8%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +50.2%

Total return

+50.2%

Start / end P/E

13.6x → 15.1x

EPS bridge

221.00 → 298.00

Residual

+4.0%

EPS growth+34.8%
Multiple rerating+11.4%
Dividend+0.0%
Residual / FX / buybacks / cross-term+4.0%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.